Humacyte misses Q2 revenue estimates, net loss narrows

Overview

• Humacyte Q2 revenue of $0.3 mln missed analyst expectations, per LSEG data

• Net loss for Q2 narrows to $37.7 mln, but misses analyst estimates, per LSEG data

• Co achieved significant progress in Symvess market launch with VAC and ECAT approvals

Outlook

• Company plans to submit supplemental BLA in 2026 for Symvess AV access

• Humacyte sees acceleration in VAC approvals for Symvess

• Company in discussions with additional DOD facilities for Symvess sales

• Humacyte plans further clinical trials for ATEV in dialysis

Result Drivers

• VAC APPROVALS - Significant increase in VAC approvals expanded Symvess eligibility from 5 to 82 civilian hospitals, per CEO Laura Niklason

• ECAT LISTING - ECAT approval enables Symvess availability at 35 Military Treatment Facilities and 160 VA hospitals

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Humacyte Inc is $6.50, about 61.8% above its August 8 closing price of $2.48

Press Release: ID:nGNXbh8Mqq